---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-004068"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2026-06-11T20:00:49+00:00"
generated_at: "2026-06-11T20:02:39.226912+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Stockholders re-elect Schuetz & Lindahl, ratify CohnReznick, approve exec compensation

## Summary
- Thomas J. Schuetz elected with 102,984,184 for, 18,837,499 withheld; Richard S. Lindahl with 103,453,540 for, 18,368,143 withheld.
- CohnReznick LLP ratified as independent auditor for FY 2026 (137,896,097 for, 181,037 against).
- Non-binding advisory vote on executive compensation approved (117,963,684 for, 1,796,022 against).
- Shareholders voted for annual say-on-pay frequency (118,289,260 for every year); board adopted annual frequency.
- All proposals passed with no surprises; broker non-votes reported for director elections and say-on-pay.

## SEC filing metadata
- accession: 0001171843-26-004068
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2026-06-11T20:00:49+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184326004068/0001171843-26-004068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184326004068/f8k_061126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-004068
- JSON: https://secwatch.observer/filing/0001171843-26-004068.json
- Plain text: https://secwatch.observer/filing/0001171843-26-004068.txt

## Key facts
- Shareholder Votes
  Compass Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm (CohnReznick, LLP) at the 2026-06-10 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: Proposal No. 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of CohnReznick, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, by the votes set forth in the table below: For Against Withheld Broker Non-votes 137,896,097 181,037 5,064,867 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184326004068/0001171843-26-004068-index.htm
- Shareholder Votes
  Compass Therapeutics, Inc. shareholders approved Non-binding, Advisory Vote on the Holding of the Future Advisory Votes on the Compensation of our Named Executive Officers at the 2026-06-10 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: Proposal No. 4. Non-binding, Advisory Vote on the Holding of the Future Advisory Votes on the Compensation of our Named Executive Officers. The stockholders voted, on a non-binding, advisory basis, to hold such advisory votes annually, by the votes set forth in the table below: Every Year Every Two Years Every Three Years Abstain 118,289,260 811,275 1,491,631 1,229,517
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184326004068/0001171843-26-004068-index.htm
- Shareholder Votes
  Compass Therapeutics, Inc. shareholders approved Non-binding, Advisory Vote on the Compensation of our Named Executive Officers at the 2026-06-10 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: Proposal No. 3. Non-binding, Advisory Vote on the Compensation of our Named Executive Officers. The stockholders voted to approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, by the votes set forth in the table below: For Against Abstain Broker Non-votes 117,963,684 1,796,022 2,061,977 21,320,318
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184326004068/0001171843-26-004068-index.htm
- Shareholder Votes
  Compass Therapeutics, Inc. shareholders approved Election of two Class III nominees for director at the 2026-06-10 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: Proposal No. 1. Election of Directors. The stockholders elected the two Class III nominees for director to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, by the votes set forth in the table below: Name For Withheld Broker Non-votes Thomas J. Schuetz, M.D., Ph.D. 102,984,184 18,837,499 21,320,318 Richard S. Lindahl, M.B.A. 103,453,540 18,368,143 21,320,318
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184326004068/0001171843-26-004068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.